Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 287

1.

Cell of Origin and Immunologic Events in the Pathogenesis of Breast Implant-Associated Anaplastic Large-Cell Lymphoma.

Turner SD, Inghirami G, Miranda RN, Kadin ME.

Am J Pathol. 2020 Jan;190(1):2-10. doi: 10.1016/j.ajpath.2019.09.005. Epub 2019 Oct 11. Review.

2.

Comparative Analysis of Cytokines of Tumor Cell Lines, Malignant and Benign Effusions Around Breast Implants.

Kadin ME, Morgan J, Kouttab N, Xu H, Adams WP, Glicksman C, McGuire P, Sieber D, Epstein AL, Miranda RN, Clemens MW.

Aesthet Surg J. 2019 Sep 7. pii: sjz243. doi: 10.1093/asj/sjz243. [Epub ahead of print]

PMID:
31589747
3.

Prevalence of atopy and staphylococcal superantigen-specific immunoglobulin E (IgE) antibodies and total serum IgE in primary cutaneous T- and B-cell lymphoma.

Vonderheid EC, Hamilton RG, Kadin ME.

J Dermatol. 2019 Dec;46(12):1170-1178. doi: 10.1111/1346-8138.15059. Epub 2019 Oct 6.

PMID:
31587349
4.

Does Breast Implant-Associated ALCL Begin as a Lymphoproliferative Disorder?

Kadin ME, Adams WP Jr, Inghirami G, Di Napoli A.

Plast Reconstr Surg. 2020 Jan;145(1):30e-38e. doi: 10.1097/PRS.0000000000006390.

PMID:
31577659
5.

A histo-immunopathologic and prognostic study of erythrodermic cutaneous T-cell lymphoma.

Vonderheid EC, Kantor GR, Telang GH, Bujanouskas P, Kadin ME.

J Cutan Pathol. 2019 Dec;46(12):913-924. doi: 10.1111/cup.13564. Epub 2019 Sep 4.

PMID:
31403211
6.

Synchronous Breast Implant-associated Anaplastic Large Cell Lymphoma and Invasive Carcinoma: Genomic Profiling and Management Implications.

Mukhtar RA, Holland M, Sieber DA, Wen KW, Rugo HS, Kadin ME, Bean GR.

Plast Reconstr Surg Glob Open. 2019 Apr 4;7(4):e2188. doi: 10.1097/GOX.0000000000002188. eCollection 2019 Apr.

7.

Commentary on: A Case Report of a Breast Implant-Associated Plasmacytoma and Literature Review of Non-ALCL Breast Implant-Associated Neoplasms.

Kadin ME.

Aesthet Surg J. 2019 Jun 21;39(7):NP240-NP242. doi: 10.1093/asj/sjz049. No abstract available.

PMID:
31220209
8.

A novel model of controlling PD-L1 expression in ALK+ anaplastic large cell lymphoma revealed by CRISPR screening.

Zhang JP, Song Z, Wang HB, Lang L, Yang YZ, Xiao W, Webster DE, Wei W, Barta SK, Kadin ME, Staudt LM, Nakagawa M, Yang Y.

Blood. 2019 Jul 11;134(2):171-185. doi: 10.1182/blood.2019001043. Epub 2019 May 31.

PMID:
31151983
9.

Recurrent MSC E116K mutations in ALK-negative anaplastic large cell lymphoma.

Luchtel RA, Zimmermann MT, Hu G, Dasari S, Jiang M, Oishi N, Jacobs HK, Zeng Y, Hundal T, Rech KL, Ketterling RP, Lee JH, Eckloff BW, Yan H, Gaonkar KS, Tian S, Ye Z, Kadin ME, Sidhu J, Jiang L, Voss J, Link BK, Syrbu SI, Facchetti F, Bennani NN, Slager SL, Ordog T, Kocher JP, Cerhan JR, Ansell SM, Feldman AL.

Blood. 2019 Jun 27;133(26):2776-2789. doi: 10.1182/blood.2019000626. Epub 2019 May 17.

PMID:
31101622
10.

Validation of a CD30 Enzyme-Linked Immunosorbant Assay for the Rapid Detection of Breast Implant-Associated Anaplastic Large Cell Lymphoma.

Hanson SE, Hassid VJ, Branch-Brooks C, Liu J, Kadin ME, Miranda R, Butler CE, Clemens MW.

Aesthet Surg J. 2019 Feb 21. pii: sjy327. doi: 10.1093/asj/sjy327. [Epub ahead of print]

PMID:
30789639
11.

What Cytokines Can Tell Us About the Pathogenesis of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL).

Kadin ME.

Aesthet Surg J. 2019 Jan 31;39(Supplement_1):S28-S35. doi: 10.1093/asj/sjy250.

PMID:
30715174
12.

IL-13 is produced by tumor cells in breast implant-associated anaplastic large cell lymphoma: implications for pathogenesis.

Kadin ME, Morgan J, Xu H, Epstein AL, Sieber D, Hubbard BA, Adams WP Jr, Bacchi CE, Goes JCS, Clemens MW, Medeiros LJ, Miranda RN.

Hum Pathol. 2018 Aug;78:54-62. doi: 10.1016/j.humpath.2018.04.007. Epub 2018 Apr 22.

PMID:
29689246
13.

SATB1 Defines a Subtype of Cutaneous CD30+ Lymphoproliferative Disorders Associated with a T-Helper 17 Cytokine Profile.

Sun J, Yi S, Qiu L, Fu W, Wang A, Liu F, Wang L, Wang T, Chen H, Wang L, Kadin ME, Tu P, Wang Y.

J Invest Dermatol. 2018 Aug;138(8):1795-1804. doi: 10.1016/j.jid.2018.02.028. Epub 2018 Mar 3.

14.

Dual Role of EZH2 in Cutaneous Anaplastic Large Cell Lymphoma: Promoting Tumor Cell Survival and Regulating Tumor Microenvironment.

Yi S, Sun J, Qiu L, Fu W, Wang A, Liu X, Yang Y, Kadin ME, Tu P, Wang Y.

J Invest Dermatol. 2018 May;138(5):1126-1136. doi: 10.1016/j.jid.2017.10.036. Epub 2017 Dec 15.

PMID:
29248547
15.

Commentary on: Breast Implant-Associated Anaplastic Large-Cell Lymphoma in a Transgender Woman.

Kadin ME, Glicksman CA.

Aesthet Surg J. 2017 Sep 1;37(8):NP88-NP89. doi: 10.1093/asj/sjx105. No abstract available.

PMID:
29036946
16.

Chimeric antigen receptor modified T cells that target chemokine receptor CCR4 as a therapeutic modality for T-cell malignancies.

Perera LP, Zhang M, Nakagawa M, Petrus MN, Maeda M, Kadin ME, Waldmann TA, Perera PY.

Am J Hematol. 2017 Sep;92(9):892-901. doi: 10.1002/ajh.24794. Epub 2017 Jun 5.

17.

Retinoic acid receptor alpha drives cell cycle progression and is associated with increased sensitivity to retinoids in T-cell lymphoma.

Wang X, Dasari S, Nowakowski GS, Lazaridis KN, Wieben ED, Kadin ME, Feldman AL, Boddicker RL.

Oncotarget. 2017 Apr 18;8(16):26245-26255. doi: 10.18632/oncotarget.15441.

18.

Biological and clinical significance of tryptophan-catabolizing enzymes in cutaneous T-cell lymphomas.

Maliniemi P, Laukkanen K, Väkevä L, Dettmer K, Lipsanen T, Jeskanen L, Bessede A, Oefner PJ, Kadin ME, Ranki A.

Oncoimmunology. 2017 Feb 10;6(3):e1273310. doi: 10.1080/2162402X.2016.1273310. eCollection 2017.

19.

CD30+ T Cells in Late Seroma May Not Be Diagnostic of Breast Implant-Associated Anaplastic Large Cell Lymphoma.

Kadin ME, Morgan J, Xu H, Glicksman CA.

Aesthet Surg J. 2017 Jul 1;37(7):771-775. doi: 10.1093/asj/sjw286.

PMID:
28402493
20.

Cytokine receptor signaling is required for the survival of ALK- anaplastic large cell lymphoma, even in the presence of JAK1/STAT3 mutations.

Chen J, Zhang Y, Petrus MN, Xiao W, Nicolae A, Raffeld M, Pittaluga S, Bamford RN, Nakagawa M, Ouyang ST, Epstein AL, Kadin ME, Del Mistro A, Woessner R, Jaffe ES, Waldmann TA.

Proc Natl Acad Sci U S A. 2017 Apr 11;114(15):3975-3980. doi: 10.1073/pnas.1700682114. Epub 2017 Mar 29.

21.

Primary cutaneous anaplastic large cell lymphoma with intralymphatic involvement associated with chronic lymphedema.

Fan P, Nong L, Sun J, Liu X, Kadin ME, Li T, Tu P, Wang Y.

J Cutan Pathol. 2017 Jul;44(7):616-619. doi: 10.1111/cup.12933. Epub 2017 May 5.

PMID:
28337783
22.

Expression of p63 protein in anaplastic large cell lymphoma: implications for genetic subtyping.

Wang X, Boddicker RL, Dasari S, Sidhu JS, Kadin ME, Macon WR, Ansell SM, Ketterling RP, Rech KL, Feldman AL.

Hum Pathol. 2017 Jun;64:19-27. doi: 10.1016/j.humpath.2017.01.003. Epub 2017 Jan 30.

23.

CD30 Induces Heat Shock Protein 90 and Signal Integration in Classic Hodgkin Lymphoma Cells.

Watanabe M, Nakano K, Kadin ME, Higashihara M, Watanabe T, Horie R.

Am J Pathol. 2017 Jan;187(1):163-175. doi: 10.1016/j.ajpath.2016.09.007. Epub 2016 Nov 19.

PMID:
27870927
24.

Intrahepatic Xenograft of Cutaneous T-Cell Lymphoma Cell Lines: A Useful Model for Rapid Biological and Therapeutic Evaluation.

Andrique L, Poglio S, Prochazkova-Carlotti M, Kadin ME, Giese A, Idrissi Y, Beylot-Barry M, Merlio JP, Chevret E.

Am J Pathol. 2016 Jul;186(7):1775-1785. doi: 10.1016/j.ajpath.2016.03.012. Epub 2016 May 13.

25.

Th17 cytokine differentiation and loss of plasticity after SOCS1 inactivation in a cutaneous T-cell lymphoma.

Ehrentraut S, Schneider B, Nagel S, Pommerenke C, Quentmeier H, Geffers R, Feist M, Kaufmann M, Meyer C, Kadin ME, Drexler HG, MacLeod RA.

Oncotarget. 2016 Jun 7;7(23):34201-16. doi: 10.18632/oncotarget.9077.

26.

KIR3DL2 (CD158k) is a potential therapeutic target in primary cutaneous anaplastic large-cell lymphoma.

Battistella M, Janin A, Jean-Louis F, Collomb C, Leboeuf C, Sicard H, Bonnafous C, Dujardin A, Ram-Wolff C, Kadin ME, Bensussan A, Bagot M, Michel L.

Br J Dermatol. 2016 Aug;175(2):325-33. doi: 10.1111/bjd.14626. Epub 2016 Jul 13.

PMID:
27037558
27.

Biomarkers Provide Clues to Early Events in the Pathogenesis of Breast Implant-Associated Anaplastic Large Cell Lymphoma.

Kadin ME, Deva A, Xu H, Morgan J, Khare P, MacLeod RA, Van Natta BW, Adams WP Jr, Brody GS, Epstein AL.

Aesthet Surg J. 2016 Jul;36(7):773-81. doi: 10.1093/asj/sjw023. Epub 2016 Mar 15.

PMID:
26979456
28.

Bacterial Biofilm Infection Detected in Breast Implant-Associated Anaplastic Large-Cell Lymphoma.

Hu H, Johani K, Almatroudi A, Vickery K, Van Natta B, Kadin ME, Brody G, Clemens M, Cheah CY, Lade S, Joshi PA, Prince HM, Deva AK.

Plast Reconstr Surg. 2016 Jun;137(6):1659-69. doi: 10.1097/PRS.0000000000002010.

PMID:
26890506
29.

Commentary about papular mycosis fungoides, lymphomatoid papulosis and lymphomatoid pityriasis lichenoides: more similarities than differences.

Vonderheid EC, Kadin ME, Telang GH.

J Cutan Pathol. 2016 Apr;43(4):303-12. doi: 10.1111/cup.12653. Epub 2015 Dec 22. Review. No abstract available.

PMID:
26566599
30.

Brefeldin A exerts differential effects on anaplastic lymphoma kinase positive anaplastic large cell lymphoma and classical Hodgkin lymphoma cell lines.

Toda T, Watanabe M, Kawato J, Kadin ME, Higashihara M, Kunisada T, Umezawa K, Horie R.

Br J Haematol. 2015 Sep;170(6):837-46. doi: 10.1111/bjh.13508. Epub 2015 Jun 24.

PMID:
26105086
31.

CD30-rich transformed mycosis fungoides or anaplastic large cell lymphoma? How to get it right.

Kadin ME.

Br J Dermatol. 2015 Jun;172(6):1478-1479. doi: 10.1111/bjd.13808. No abstract available.

PMID:
26036155
32.

CD30(+) cutaneous lymphoproliferative disorders with pseudocarcinomatous hyperplasia are associated with a T-helper-17 cytokine profile and infiltrating granulocytes.

Guitart J, Martinez-Escala ME, Deonizio JM, Gerami P, Kadin ME.

J Am Acad Dermatol. 2015 Mar;72(3):508-15. doi: 10.1016/j.jaad.2014.11.021. Epub 2015 Jan 10.

PMID:
25582534
33.

Deficient cutaneous antibacterial competence in cutaneous T-cell lymphomas: role of Th2-mediated biased Th17 function.

Wolk K, Mitsui H, Witte K, Gellrich S, Gulati N, Humme D, Witte E, Gonsior M, Beyer M, Kadin ME, Volk HD, Krueger JG, Sterry W, Sabat R.

Clin Cancer Res. 2014 Nov 1;20(21):5507-16. doi: 10.1158/1078-0432.CCR-14-0707. Epub 2014 Sep 11.

34.

Etiologic heterogeneity among non-Hodgkin lymphoma subtypes: the InterLymph Non-Hodgkin Lymphoma Subtypes Project.

Morton LM, Slager SL, Cerhan JR, Wang SS, Vajdic CM, Skibola CF, Bracci PM, de Sanjosé S, Smedby KE, Chiu BC, Zhang Y, Mbulaiteye SM, Monnereau A, Turner JJ, Clavel J, Adami HO, Chang ET, Glimelius B, Hjalgrim H, Melbye M, Crosignani P, di Lollo S, Miligi L, Nanni O, Ramazzotti V, Rodella S, Costantini AS, Stagnaro E, Tumino R, Vindigni C, Vineis P, Becker N, Benavente Y, Boffetta P, Brennan P, Cocco P, Foretova L, Maynadié M, Nieters A, Staines A, Colt JS, Cozen W, Davis S, de Roos AJ, Hartge P, Rothman N, Severson RK, Holly EA, Call TG, Feldman AL, Habermann TM, Liebow M, Blair A, Cantor KP, Kane EV, Lightfoot T, Roman E, Smith A, Brooks-Wilson A, Connors JM, Gascoyne RD, Spinelli JJ, Armstrong BK, Kricker A, Holford TR, Lan Q, Zheng T, Orsi L, Dal Maso L, Franceschi S, La Vecchia C, Negri E, Serraino D, Bernstein L, Levine A, Friedberg JW, Kelly JL, Berndt SI, Birmann BM, Clarke CA, Flowers CR, Foran JM, Kadin ME, Paltiel O, Weisenburger DD, Linet MS, Sampson JN.

J Natl Cancer Inst Monogr. 2014 Aug;2014(48):130-44. doi: 10.1093/jncimonographs/lgu013.

35.

Medical history, lifestyle, family history, and occupational risk factors for mycosis fungoides and Sézary syndrome: the InterLymph Non-Hodgkin Lymphoma Subtypes Project.

Aschebrook-Kilfoy B, Cocco P, La Vecchia C, Chang ET, Vajdic CM, Kadin ME, Spinelli JJ, Morton LM, Kane EV, Sampson JN, Kasten C, Feldman AL, Wang SS, Zhang Y.

J Natl Cancer Inst Monogr. 2014 Aug;2014(48):98-105. doi: 10.1093/jncimonographs/lgu008.

36.

Medical history, lifestyle, family history, and occupational risk factors for peripheral T-cell lymphomas: the InterLymph Non-Hodgkin Lymphoma Subtypes Project.

Wang SS, Flowers CR, Kadin ME, Chang ET, Hughes AM, Ansell SM, Feldman AL, Lightfoot T, Boffetta P, Melbye M, Lan Q, Sampson JN, Morton LM, Zhang Y, Weisenburger DD.

J Natl Cancer Inst Monogr. 2014 Aug;2014(48):66-75. doi: 10.1093/jncimonographs/lgu012.

37.

Rationale and Design of the International Lymphoma Epidemiology Consortium (InterLymph) Non-Hodgkin Lymphoma Subtypes Project.

Morton LM, Sampson JN, Cerhan JR, Turner JJ, Vajdic CM, Wang SS, Smedby KE, de Sanjosé S, Monnereau A, Benavente Y, Bracci PM, Chiu BC, Skibola CF, Zhang Y, Mbulaiteye SM, Spriggs M, Robinson D, Norman AD, Kane EV, Spinelli JJ, Kelly JL, La Vecchia C, Dal Maso L, Maynadié M, Kadin ME, Cocco P, Costantini AS, Clarke CA, Roman E, Miligi L, Colt JS, Berndt SI, Mannetje A, de Roos AJ, Kricker A, Nieters A, Franceschi S, Melbye M, Boffetta P, Clavel J, Linet MS, Weisenburger DD, Slager SL.

J Natl Cancer Inst Monogr. 2014 Aug;2014(48):1-14. doi: 10.1093/jncimonographs/lgu005.

38.

γδ T-cell-rich variants of pityriasis lichenoides and lymphomatoid papulosis: benign cutaneous disorders to be distinguished from aggressive cutaneous γδ T-cell lymphomas.

Martinez-Escala ME, Sidiropoulos M, Deonizio J, Gerami P, Kadin ME, Guitart J.

Br J Dermatol. 2015 Feb;172(2):372-9. doi: 10.1111/bjd.13364. Epub 2014 Dec 15.

PMID:
25143223
39.

IL-19 is a component of the pathogenetic IL-23/IL-17 cascade in psoriasis.

Witte E, Kokolakis G, Witte K, Philipp S, Doecke WD, Babel N, Wittig BM, Warszawska K, Kurek A, Erdmann-Keding M, Kunz S, Asadullah K, Kadin ME, Volk HD, Sterry W, Wolk K, Sabat R.

J Invest Dermatol. 2014 Nov;134(11):2757-2767. doi: 10.1038/jid.2014.308. Epub 2014 Jul 21.

40.

Large-cell transformation of mycosis fungoides-differential diagnosis with implications for clinical management: a consensus statement of the US Cutaneous Lymphoma Consortium.

Kadin ME, Hughey LC, Wood GS.

J Am Acad Dermatol. 2014 Feb;70(2):374-6. doi: 10.1016/j.jaad.2013.09.007. No abstract available.

PMID:
24438952
41.

Chromosomal rearrangements of 6p25.3 define a new subtype of lymphomatoid papulosis.

Karai LJ, Kadin ME, Hsi ED, Sluzevich JC, Ketterling RP, Knudson RA, Feldman AL.

Am J Surg Pathol. 2013 Aug;37(8):1173-81. doi: 10.1097/PAS.0b013e318282d01e.

PMID:
23648461
42.

Prognostic factors and risk stratification in early mycosis fungoides.

Vonderheid EC, Pavlov I, Delgado JC, Martins TB, Telang GH, Hess AD, Kadin ME.

Leuk Lymphoma. 2014 Jan;55(1):44-50. doi: 10.3109/10428194.2013.790541. Epub 2013 May 7.

PMID:
23547839
43.

t(8;9)(p22;p24)/PCM1-JAK2 activates SOCS2 and SOCS3 via STAT5.

Ehrentraut S, Nagel S, Scherr ME, Schneider B, Quentmeier H, Geffers R, Kaufmann M, Meyer C, Prochorec-Sobieszek M, Ketterling RP, Knudson RA, Feldman AL, Kadin ME, Drexler HG, MacLeod RA.

PLoS One. 2013;8(1):e53767. doi: 10.1371/journal.pone.0053767. Epub 2013 Jan 23.

44.

Genome-wide analysis reveals recurrent structural abnormalities of TP63 and other p53-related genes in peripheral T-cell lymphomas.

Vasmatzis G, Johnson SH, Knudson RA, Ketterling RP, Braggio E, Fonseca R, Viswanatha DS, Law ME, Kip NS, Ozsan N, Grebe SK, Frederick LA, Eckloff BW, Thompson EA, Kadin ME, Milosevic D, Porcher JC, Asmann YW, Smith DI, Kovtun IV, Ansell SM, Dogan A, Feldman AL.

Blood. 2012 Sep 13;120(11):2280-9. doi: 10.1182/blood-2012-03-419937. Epub 2012 Aug 1.

45.

Long-term results of CCG 5942: a randomized comparison of chemotherapy with and without radiotherapy for children with Hodgkin's lymphoma--a report from the Children's Oncology Group.

Wolden SL, Chen L, Kelly KM, Herzog P, Gilchrist GS, Thomson J, Sposto R, Kadin ME, Hutchinson RJ, Nachman J.

J Clin Oncol. 2012 Sep 10;30(26):3174-80. doi: 10.1200/JCO.2011.41.1819. Epub 2012 May 29.

46.

Ets-1 activates overexpression of JunB and CD30 in Hodgkin's lymphoma and anaplastic large-cell lymphoma.

Watanabe M, Itoh K, Togano T, Kadin ME, Watanabe T, Higashihara M, Horie R.

Am J Pathol. 2012 Feb;180(2):831-8. doi: 10.1016/j.ajpath.2011.10.007. Epub 2011 Nov 19.

47.

High soluble CD30, CD25, and IL-6 may identify patients with worse survival in CD30+ cutaneous lymphomas and early mycosis fungoides.

Kadin ME, Pavlov IY, Delgado JC, Vonderheid EC.

J Invest Dermatol. 2012 Mar;132(3 Pt 1):703-10. doi: 10.1038/jid.2011.351. Epub 2011 Nov 10.

48.

Lymphomatoid papulosis followed by pityriasis lichenoides: a common pathogenesis?

Vonderheid EC, Kadin ME, Gocke CD.

Am J Dermatopathol. 2011 Dec;33(8):835-40. doi: 10.1097/DAD.0b013e3181f4d8c3.

PMID:
22042257
49.

Targeted repression of overexpressed CD30 downregulates NF-kappaB and ERK1/2 pathway in Hodgkin lymphoma cell lines.

Watanabe M, Nakano K, Togano T, Nakashima M, Higashihara M, Kadin ME, Watanabe T, Horie R.

Oncol Res. 2011;19(10-11):463-9.

PMID:
22715589
50.

Hodgkin's lymphoma therapy: past, present, and future.

Rathore B, Kadin ME.

Expert Opin Pharmacother. 2010 Dec;11(17):2891-906. doi: 10.1517/14656566.2010.515979. Review.

Supplemental Content

Loading ...
Support Center